Ballentine Partners LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR)

Ballentine Partners LLC purchased a new stake in ProQR Therapeutics (NASDAQ:PRQRFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,035 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PRQR. OneDigital Investment Advisors LLC increased its position in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares during the period. BNP Paribas Financial Markets grew its stake in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. increased its stake in ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PRQR has been the subject of several research reports. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer began coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price objective on the stock. Finally, Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.83.

Get Our Latest Stock Report on ProQR Therapeutics

ProQR Therapeutics Trading Down 0.5 %

Shares of NASDAQ PRQR opened at $2.16 on Monday. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62. The firm has a fifty day simple moving average of $2.93 and a two-hundred day simple moving average of $2.56. The firm has a market capitalization of $176.43 million, a PE ratio of -6.75 and a beta of 0.30.

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. The company had revenue of $4.22 million during the quarter, compared to analyst estimates of $4.75 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. On average, sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current year.

About ProQR Therapeutics

(Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Recommended Stories

Institutional Ownership by Quarter for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.